{"url_path":"/sec/ogen/10-q/2026/item-2","section_key":"item-2","section_title":"Item 2 **","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-08","source_url":"https://www.sec.gov/Archives/edgar/data/1174940/0001493152-26-021967-index.html","accession_number":"0001493152-26-021967","cik":"0001174940","ticker":"OGEN","issuer_name":"ORAGENICS INC","edgar_url":"https://www.sec.gov/Archives/edgar/data/1174940/0001493152-26-021967-index.html","primary_entity_key":"0001174940","primary_entity_name":"ORAGENICS INC"},"word_count":83,"has_tables":true,"body_markdown":"**ITEM\n2.**\n**UNREGISTERED\nSALES OF EQUITY SECURITIES AND USE OF PROCEEDS**\n\n \n\nEffective as of March 13, 2026, the Company issued\n5,000 shares of Common Stock to Dawson James in payment of advisory fees pursuant to an Engagement Agreement dated as of March 13, 2026,\nat a price of $1.00 per share. The Company relied upon the exemption from registration provided under Section 4(a)(2) of the\nSecurities Act of 1933, as amended, for transactions not involving a public offering, and Rule 506(b) promulgated thereunder."}